Investors

An important element of FibroGen's financial strategy is to assure adequate funding of Company operations and to maintain 3-5 years of cash compared to burn rate. Since its inception, FibroGen has been able to raise sufficient capital to maintain a margin of safety against its core burn rate. A variety of sources of financing have been used to accomplish this including private equity and financing grants related to FibroGen's subsidiary FibroGen Europe Corp.

Selected major investors in FibroGen have included:

  • Adage Capital Management
  • Apothecary Capital
  • Astellas Pharma, Inc.
  • Brookside Capital Partners (an affiliate of Bain Capital)
  • BankInvest Biomedical Development
  • Bio Fund Ventures II OY / Mgmt Oy
  • Corriente Biotechnology Partners
  • Credit Suisse London Nominees
  • Duquesne Capital Management
  • Franklin Fairview
  • Franklin Templeton
  • Goldman Sachs
  • IBELIN PTE Investments
  • Janus Capital Group
  • New Ventures
  • Och-Ziff Capital Management
  • Peninsula Group
  • Pictet Bank
  • Privat Kredit Bank
  • Ridgeback Capital
  • The Rosewood Corporation
  • Sedgefield Investments
  • SITRA
  • SMBC Capital (the private equity arm of Sumitomo Mitsui Banking Corporation)
  • Taisho Pharmaceutical Co., Ltd.
  • Three Arch Bay Health Science Fund I, L.P.
  • T. Rowe Price
  • VCFA Holdings
  • Wagner & Brown